MetaCap

AstraZeneca (AZN) vs Novartis (NVS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Novartis (NVS) has outperformed AstraZeneca (AZN) over the past year, gaining 18.2% versus a loss of 4.2%. Over five years, NVS leads with a +86.5% price change compared with +54.1% for AZN. Novartis is the larger company by market cap ($284.18 billion vs $270.40 billion), about 1.1 times the size.

On valuation, Novartis trades at a lower forward P/E (15.1x vs 15.4x for AstraZeneca). Novartis offers the higher dividend yield (3.10% vs 1.85%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZN-4.20%NVS+18.19%
+35%+9%-17%
Nov 21, 20251 yearNov 20, 2026
AZN+53.86%NVS+84.26%
+112%+50%-13%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZN versus NVS key metrics
MetricAZNNVS
Share price$174.35$150.47
Market cap$270.40B$284.18B
1-day change-0.60%-0.50%
YTD return-5.17%+9.14%
1-year return-4.20%+18.19%
5-year return+54.07%+86.46%
P/E ratio (TTM)24.6628.72
Forward P/E15.4115.15
EPS (TTM)$7.07$5.24
Dividend yield1.85%3.10%
Annual dividend$3.23$4.67
Revenue (latest FY)$58.74B—
Revenue growth (YoY)+8.63%—
Net income (latest FY)$10.22B$13.98B
Gross margin81.90%—
Operating margin23.40%—
Net margin17.41%—
52-week high$212.71$170.46
52-week low$153.41$126.50
Distance from 52-week high-18.03%-11.73%
Analyst consensusbuyhold
Avg. price target upside+20.40%+4.41%
Average volume2.93M2.18M
Shares outstanding1.55B1.89B
Employees96,10075,267
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • NVS has outperformed AZN by 22.4 percentage points over the past year.
  • Novartis offers a meaningfully higher dividend yield (3.10% vs 1.85%).

About AstraZeneca

AZN stock →

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.

Health Care · Biotechnology: Pharmaceutical Preparations · 96,100 employees

About Novartis

NVS stock →

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients; Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,267 employees

AZN vs NVS FAQ

Which is bigger, AstraZeneca or Novartis?

Novartis (NVS) is larger, with a market capitalization of $284.18B compared with $270.40B for AstraZeneca (AZN).

Which stock has performed better over the past year, AZN or NVS?

NVS returned +18.19% over the past 12 months, compared with -4.20% for AZN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AZN or NVS?

AZN has the lower trailing P/E at 24.7, versus 28.7 for NVS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, AstraZeneca or Novartis?

Novartis has the higher yield at 3.10%, compared with 1.85% for AstraZeneca.

Are AstraZeneca and Novartis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons